Skip to main content
Quest Diagnostics

Validation of a Blood Test for Multi-Cancer Risk Stratification in a Lung Cancer Screening Cohort

Validation of a Blood Test for Multi-Cancer Risk Stratification in a Lung Cancer Screening Cohort

Authors: Fahrmann JF, Irajizad E, Rudsari H, Vykoukal J, Toumazis I, Khorami-Sarvestani S, Ansari S, Yang J, Kettner N, Dennison JB, Ostrin E, Hanash S

Citation: medRxiv [Preprint]. 2025 Nov 23:2025.11.20.25340518. doi: 10.1101/2025.11.20.25340518.

Specialties: Oncology

Related content

Publication
Passenger Mutations Link Cellular Origin and Transcriptional Identity in Human Lung Adenocarcinomas
Publication
Learning the Cellular Origins Across Cancers Using Single-Cell Chromatin Landscapes
Audio Podcast
Enhancing Cancer Treatment Decisions With Ultrasensitive MRD Testing
Audio Podcast
Optimize Oncology Care with Clinical Pathways
Publication
Evolution and Co-Occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.